Drug-related Problems and their Predictors among Breast Cancer Patients Receiving Chemotherapy in National Cancer Institute, Malaysia

被引:0
|
作者
Abdulrahman, Egbal [1 ]
Kassab, Yaman Walid [1 ]
Jamaluddln, Nurul Adilla Hayat [1 ]
Iqbal, Muhammad Shahid [2 ]
Khan, Salah-Ud-Din [3 ]
Al-Saikan, Fahad, I [2 ]
Ahmed, M. Azmin [4 ]
机构
[1] Univ Cyberjaya, Dept Hosp & Clin Practice, Fac Pharm, Cyberjaya 63000, Selangor, Malaysia
[2] Prince Sattam bin Abdulaziz Univ, Coll Pharm, Dept Clin Pharm, Al Kharj 11942, Saudi Arabia
[3] Imam Mohammad Ibn Saud Islamic Univ, Coll Med, Dept Biochem, Riyadh, Saudi Arabia
[4] Univ Malaysia, Sch Pharm, Kuala Lumpur, Malaysia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2021年 / 40卷 / 03期
关键词
adverse drug reactions (ADRs); breast cancer; drug-related problems (DRPs); National Cancer Institute (IKN); risk factors; EVENTS; ERRORS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer patients receiving chemotherapy are at high risk of drug-related problems (DRPs), as it is estimated that around 5-10% of hospital admissions are due to DRPs. Breast cancer management is a leading cause of these DRPs in which the drug toxicity is considered as the main cause that makes DRPs very prevalent. Hence, this study aimed to assess DRPs and their predictors among breast cancer patients receiving chemotherapy at the National Cancer Institute (IKN), Malaysia. Breast cancer patients with any stage and type aged >= 18 years and receiving chemotherapy between January and December 2017 were included. DRPs were classified according to a modified form of the Pharmaceutical Care Network Europe (PCNE). Statistical analysis was done by Statistical Package for Social Science (SPSS) software version 24. For categorical data, the Chi-squared test was used to determine the association of patients' characteristics and the occurrence of DRPs. A p < 0.05 was assumed as statistically significant among the obtained results. Overall, 100 patients were included in the study. The majority was Malays 59 (59%) and aged between 25-67 years. A total of 157 DRPs were identified in 78 patients, translating to a prevalence of 78%. Adverse drug reactions (ADRs) were the most common DRPs (47.8%). The most frequent ADR was neutropenia which encountered in 50 patients with prevalence 14.6% of the total ADRs followed by chemotherapy induced nausea and vomiting (CINV) 42 (12.5%). Other DRPs such as drug-drug interactions, drug selection and drug dosing were less common. It was predicted with increasing the number of co-morbidities, DRPs were more likely to occur (OR = 2.279, 95%, CI 1.098-4.730, p = 0.027). DRPs were common in breast cancer patients receiving chemotherapy. The predominant proportion of DRPs was ADRs. Number of co-morbidities was a predictor of the DRPs among the studied cohort of the patients.
引用
收藏
页码:565 / 571
页数:7
相关论文
共 50 条
  • [1] Drug-related problems associated with systemic therapy for breast cancer and their categorization
    Reineking, Nele
    Glasmacher, Anja
    Kuehr, Marietta
    Braun, Michael
    Kuhn, Walther
    Jaehde, Ulrich
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 248 - 248
  • [2] Predictors of Sexual Adjustment in Cancer Patients Receiving Chemotherapy
    Park, Eun-Young
    Kim, Jung-Hee
    JOURNAL OF PSYCHOSOCIAL ONCOLOGY, 2015, 33 (05) : 488 - 503
  • [3] Drug-related problems among hospitalized cancer pain patients: an investigative single-arm intervention trial
    Su, Ying-Jie
    Yan, Yi-Dan
    Wang, Wen-Juan
    Xu, Tao
    Gu, Zhi-Chun
    Bai, Yong-Rui
    Lin, Hou-Wen
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (02) : 2008 - 2017
  • [4] Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy
    Gandhi, Ashu
    Copson, Ellen
    Eccles, Diana
    Durcan, Lorraine
    Howell, Anthony
    Morris, Julie
    Howell, Sacha
    McDiarmid, Sarah
    Sellers, Katharine
    Evans, D. Gareth
    Harvie, Michelle
    BREAST, 2019, 45 : 1 - 6
  • [5] Longitudinal assessment of the impact of higher body mass index on cancer-related fatigue in patients with breast cancer receiving chemotherapy
    Inglis, Julia E.
    Janelsins, Michelle C.
    Culakova, Eva
    Mustian, Karen M.
    Lin, Po-Ju
    Kleckner, Ian R.
    Peppone, Luke J.
    SUPPORTIVE CARE IN CANCER, 2020, 28 (03) : 1411 - 1418
  • [6] Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy
    Razzaghdoust, Abolfazl
    Mofid, Bahram
    Peyghambarlou, Parvin
    SUPPORTIVE CARE IN CANCER, 2020, 28 (01) : 155 - 161
  • [7] Evaluation of treatment responses among subgroups of breast cancer patients receiving neoadjuvant chemotherapy
    Dagistanli, Sevinc
    Sonmez, Suleyman
    Bulut, Nilufer
    Kose, Ali Mertcan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 : S821 - S826
  • [8] Evaluation of treatment responses among subgroups of breast cancer patients receiving neoadjuvant chemotherapy
    Dagistanli, Sevinc
    Sonmez, Suleyman
    Bulut, Nilufer
    Kose, Ali Mertcan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 2) : S821 - S826
  • [9] Evaluation of the impact of anaemia on quality of life among breast cancer patients undergoing chemotherapy in Malaysia
    Muthanna, Fares Mohammed Saeed
    Hassan, Bassam Abdul Rasool
    Karuppannan, Mahmathi
    Mohammed, Ali Haider
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (02) : 310 - 312
  • [10] Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer
    Nawa-Nishigaki, Minako
    Kobayashi, Ryo
    Suzuki, Akio
    Hirose, Chiemi
    Matsuoka, Rie
    Mori, Ryutaro
    Futamura, Manabu
    Sugiyama, Tadashi
    Yoshida, Kazuhiro
    Itoh, Yoshinori
    ANTICANCER RESEARCH, 2018, 38 (02) : 877 - 884